Biography
Dr. Kim is physician-in-chief and senior vice president at City of HopeOrange County and vice physician-in-chief and professor at City of HopeNational Medical Center. Dr. Kim is an international leader in lungcancer having published over 200 peer-reviewed articles in top tierjournals. He has previously served as an associate tenured professor atThe University of Texas MD Anderson Cancer Center, Chair of Solid TumorOncology atLevineCancer Institute, Atrium Health, and obtained his MBAat theUniversity ofNorth Carolina Kenan-Flagler School of Business,ChapelHill, NC.

Talk
NA - Dr. Kim is Co - Moderator
NA - Dr. Kim is Co - Moderator

Biography
Mark Daly is the founding Chief of the Analytic and Translational Genetics Unit (ATGU) at Massachusetts General Hospital and is an assistant professor at Harvard Medical School. His research focuses on statistical and computational methods to discover and interpret genetic variation in complex disease, and on bringing genome information into clinical settings. He is also an Institute Member and Co-Director of the Program in Medical and Population Genetics at the Broad Institute, where he leads major sequencing studies in autism and inflammatory bowel disease. His group has major research efforts in neuropsychiatric genetics, particularly autism, schizophrenia, and ADHD, and has led many large GWAS and exome studies. His lab serves as an analytic hub for the Psychiatric GWAS Consortium. He has also led gene mapping in Crohns disease and ulcerative colitis. Daly served as Director of the Institute of Molecular Medicine Finland (FIMM) and received degrees from MIT and Leiden University.

Talk
Biobanks and the road ahead in human genetics
In the 20 years since the completion of the first human genome, the ability to decode the inherited basis of disease has developed rapidly. Efforts to date have uncovered tens of thousands of genetic variants affecting human disease - from rare Mendelian conditions to cancer to common, chronic diseases in nearly all clinical domains. While this work has taken another leap forward with the introduction of large-scale biobanks such as UK Biobank, FinnGen and All Of Us, it is becoming clear that while variant discovery might be considered a solved problem, our ability to define disease mechanisms and paths to therapeutic remediation from such discoveries is badly lacking. Here we will discuss the challenges to that progress and the potential of new scalable technologies to help accelerate the path from discovery to actionable understanding of mechanism required to ultimately help patients

Biography
CEO and co-founder of Oxford Nanopore Technologies, pioneering real-time,scalable DNARNA sequencing. With a PhD in bioelectronic technology, he ledthe company from spinout to global player, transforming genomics withportable sequencing devices. Sanghera champions accessible, decentralizedsequencing for research, healthcare, and public health worldwide.

Talk
In conversation with Gordon Sanghera
Gordon will chart his journey as CEO of Oxford Nanopore, from early vision and product development, through to scaling operations, navigating challenges, achieving their IPO and onward growth since then. He reflects on the importance of culture, innovation and resilient leadership, and how these strong foundations can help to drive the company forward.

Biography
J. Craig Venter is a biologist renowned for his contributions in genomics including sequencing the first draft human genome, the first complete diploid human genome, and construction of the first synthetic bacterial cell.He and his teams current research programs include continued analysis of the human genome with a focus on the intersection of the genome and all physical characteristics and how this relates to disease and health; the human microbiome; synthetic biology advances; infectious disease; and discovering and understanding genetic diversity in the worlds oceans.Dr. Venter pioneered the notion of presymptomatic testing coupled with deep genomic sequencing to assess long term health of individuals. This was the basis for the formation of Human Longevity, Inc. He is currently embarking on a quest to utilize these same concepts but focused on a great area of unmet needwomens health, to build the first of its kind, for-profit, transformative womens health center. The center will encompass standard of care testing along with state of the art genomic and imaging powered by AI to deliver the best care to all women.Dr. Venter began his formal education after a tour of duty as a Navy Corpsman in Vietnam from 1967 to 1968. After earning both a Bachelor of Science in biochemistry and a PhD in physiology and pharmacology from the University of California San Diego, he was appointed professor at the State University of New York at Buffalo and the Roswell Park Cancer Institute. In 1984, he moved to the National Institutes of Health campus where he developed expressed sequence tags or ESTs, a revolutionary new strategy for rapid gene discovery.In 1992, Dr. Venter founded The Institute for Genomic Research (TIGR, now part of JCVI), a not-for-profit research institute, where in 1995 he and his team decoded the genome of the first free-living organism, the bacterium Haemophilus influenzae, using the new whole genome shotgun technique.In 1998, Dr. Venter founded Celera Genomics to sequence the human genome using new tools and techniques he and his team developed. This research culminated with the February 2001 publication of the human genome in the journal, Science. He and his team at Celera also sequenced the fruit fly, mouse, and rat genomes.Dr. Venter is one of the most frequently cited scientists, and the author of more than 280 research articles. He is also the recipient of numerous honorary degrees, public honors, and scientific awards, including the 2008 United States National Medal of Science, the 2002 Gairdner Foundation International Award, the 2001 Paul Ehrlich and Ludwig Darmstaedter Prize, and the King Faisal International Award for Science. Dr. Venter is a member of numerous prestigious scientific organizations including the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Society for Microbiology.Dr. Venter is a serial entrepreneur who has co-founded several companies including Synthetic Genomics, Inc., (now Viridos), SGI DNA, (now Telesis Bio) and Human Longevity, Inc. (HLI).He is also the author of The Voyage of Sorcerer II: The Expedition That Unlocked the Secrets of the Oceans Microbiome (Harvard University Press, 2023), Life at the Speed of Light: From the Double Helix to the Dawn of Digital Life (Viking, 2013) and A Life Decoded: My Genome: My Life (Viking, 2007).

Biography
Ralph Snyderman served as Chancellor for Health Affairs at Duke University from 1989 to July 2004, leading the transition of this excellent medical center into an internationally recognized leader in academic medicine. He oversaw the development of the Duke University Health System and served as its first President and CEO. Dr. Snyderman has played a leading role in the conception and development of personalized healthcare, an evolving model of national healthcare delivery. He has been widely recognized for his contributions to the development of a more rational, effective, and compassionate health care. He was among the first to envision and articulate the need to shift the current focus of healthcare from treating disease events to personalized, proactive, and patient-centered care. The Association of American Medical Colleges has referred to Dr. Snyderman as the father of personalized medicine.

Biography
Brook Byers has been a venture capital investor since 1972. He has been closely involved with founders to help build more than 60 new science-based companies. He formed the first life sciences practice group in the venture capital profession in 1984 and led Kleiner Perkins to become a premier venture capital firm in the life sciences, healthcare and biotechnology sectors.Brook was the founding president and then chairman of four biotechnology companies that were incubated in Kleiner Perkins offices and went on to become public companies with an aggregate market value of more than US$8 billion. He currently serves on the board of directors of Arsenal Bio, Octave Bio, Newsela and Verana Health. Brook is a Lifetime Board Member of the University of California San Francisco Medical Center. He served on the Board of Trustees of Stanford University and the Georgia Tech Advisory Board. He received an Honorary PhD from Georgia Tech.

Biography
A world-renowned scientist and recipient of the National Medal of Science in 2011, Dr. Leroy Hood co-founded the Institute for Systems Biology (ISB) in 2000 and served as its first President from 2000-2017. In 2021, he founded Phenome Health, a non-profit research organization dedicated to contributing solutions to the major challenges causing a crisis in healthcare. In September 2023, Dr. Hood joined the Buck Institute for Research on Aging as Chief Innovation Officer and Distinguished Professor. Dr. Hood is a member of the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine. Of the more than 6,000 scientists worldwide who belong to one or more of these academies, Dr. Hood is one of only 20 people elected to all three.He is also a member of the Inventors Hall of Fame for inventing automated DNA sequencing.

Biography
Dr. Stephen Montgomery is the Stanford Medicine Endowed Professor of Pathology and Professor of Genetics, Biomedical Data Science and, by courtesy, Computer Science at Stanford University. He leads a dynamic lab where his team blends functional genomics and sophisticated bioinformatics to unravel the molecular roots of genetic diseases. His research prominently features in numerous large-scale consortia, such as GTEx and MoTrPAC.Dr. Montgomery's laboratory is renowned for developing innovative transcriptome-based methods. These breakthroughs are pivotal for uncovering impactful rare variants in diverse groups, ranging from individuals and families to broader populations. His approaches are also unique in their ability to measure gene-by-environment interactions.His expertise extends to multi-omics studies of global populations showcasing his labs commitment to inclusive and diverse genomics research. Dr. Montgomery is a leader in the discovery and interpretation of rare variants using multiomics, and his work in building genomic databases for RNA diagnostics sets him apart in the field. He is also a key contributor to the integration of long-read sequencing and RNA sequencing for more accurate variant interpretation, a technique crucial in precision medicine.

Biography
University of Oklahoma

Biography
Mark Daly is an institute member and co-director of the Program in Medicaland Population Genetics at the Broad Institute of MIT and Harvard, where heleads many large-scale genome sequencing studies in autism and inflammatorybowel disease. He is also the founding chief of the Analytic andTranslational Genetics Unit (ATGU) at Massachusetts General Hospital andassociate professor at the Harvard Medical School. His research hashistorically focused on the development and application of statisticalmethods for the discovery and interpretation of genetic variationresponsible for complex human disease, and with the creation of the ATGU,he and other core faculty are focused on the interpretation of genomesequence and the use of genome information in clinical settings.Daly wasappointed director of the Institute of Molecular Medicine Finland (FIMM) atthe University of Helsinki from February of 2018 through April 2023 whilemaintaining his lab in Boston. After that, he returned to Boston full-timeand now maintains an affiliate position as a researcher at the Universityof Helsinki. FIMM is a translational research institute focusing on cancer,digital diagnostics, genetics, and epidemiology and is home to landmarkefforts such as the FinnGen Project.In addition to developing computationaland statistical methods that can be broadly applied, Dalys group hasseveral primary medical genetics research foci. He has an extensiveresearch program in neuropsychiatric geneticsparticularly in autism,schizophrenia, and ADHDand has led large-scale genome-wide associationstudies (GWAS) and exome sequencing efforts in this area. Dalys lab and BenNeale's lab together serve as an analytic hub for the Psychiatric GWASConsortium, an international consortium leading the largest collaborativeGWAS studies in five major psychiatric disorders. Daly also has alongstanding effort in the mapping of genes for Crohns disease andulcerative colitis, through which he helped found and lead an internationaleffort that has identified more than 150 genetic risk factors and, incollaboration with Ramnik Xaviers group, pursues the functionalinterpretation and clinical ramifications of these continued gene discoveryefforts. Along with Heidi Rehm, he is co-PI of the gnomAD project and iscommitted to ensuring the output of all ATGU genomic research is maximallyaccessible and useful to the clinical and research communities.Dalyreceived his B.S. in physics from MIT and his Ph.D. in human genetics fromLeiden University, Netherlands.

Talk
Biobanks and the road ahead in human genetics
In the 20 years since the completion of the first human genome, the ability to decode the inherited basis of disease has developed rapidly. Efforts to date have uncovered tens of thousands of genetic variants affecting human disease - from rare Mendelian conditions to cancer to common, chronic diseases in nearly all clinical domains. While this work has taken another leap forward with the introduction of large-scale biobanks such as UK Biobank, FinnGen and All Of Us, it is becoming clear that while variant discovery might be considered a solved problem, our ability to define disease mechanisms and paths to therapeutic remediation from such discoveries is badly lacking. Here we will discuss the challenges to that progress and the potential of new scalable technologies to help accelerate the path from discovery to actionable understanding of mechanism required to ultimately help patients

Biography
Mark McCarthy is Executive Director of Human Genetics at Genentech, where he leads efforts within the company to use human genetics to advance the understanding of disease and further the development of novel therapeutic and preventative approaches. Prior to his move to the Bay Area in 2019, Mark was Robert Turner Professor of Diabetes Medicine at the University of Oxford. There, his research focused on genetic discovery in type 2 diabetes and related traits, and on using the causal insights derived from those analyses to drive biological inference and translational opportunities.

Biography
Dr. Hanlee P. Ji is leveraging his expertise in oncology, genetics, andengineering to drive advancements in cancer research. His work integratesmolecular technology, computational methods, and genome biology to developtargeted therapies for gastrointestinal cancers and study genomicinstability. As a senior figure at the Stanford Genome Technology Center,Dr. Ji's research encompasses immunogenomics, kinase interactions fortargeted therapy, and innovative data storage using DNA technologies. He isalso involved in clinical trials and translational genomics, aiming tobring scientific discoveries from bench to bedside.

Biography
CEO and co-founder of Oxford Nanopore Technologies, pioneering real-time,scalable DNARNA sequencing. With a PhD in bioelectronic technology, he ledthe company from spinout to global player, transforming genomics withportable sequencing devices. Sanghera champions accessible, decentralizedsequencing for research, healthcare, and public health worldwide.

Biography
Manuel is an Assistant Professor in the Department of Biomedical Data Science at Stanford University in Stanford, California. Manuel has a Bachelor of Science in Mathematics from the Massachusetts Institute of Technology, and a Doctor of Philosophy in Human Genetics from the Nuffield Department of Clinical Medicine at Oxford University where he was a Clarendon Scholar. He did additional training at the Broad Institute in Cambridge, Massachusetts where he led the Helmsley Inflammatory Bowel Disease Exome Sequencing Program to understand the genetic factors that contribute to ulcerative colitis and Crohns disease risk.

Biography
Dr. Slavé Petrovski is a human geneticist by training with over 15 yearsexperience leading large-scale omics studies. In this time, Slavé hascontributed to shaping the field of contemporary population and statisticalgenomics, including introducing machine learningadvanced analytics toidentify numerous drug targets across a diverse range of diseases. Since2017, as the Vice President and Head of AstraZenecas Centre for GenomicsResearch (CGR) Slavé is accountable for architecting and delivering thecompanys Genomics Initiative strategy. He has built in-house capabilitiesand expertise across key domains: Bioinformatics, Statistical Genetics,Innovative AIML methods, multi-omics, and clinical sciences. Applyingthese cross-disciplinary skills to large-scale omics datasets.

Biography
Dr. Kurzrock is a boardcertified medical oncologist and a renownedexpertin precision medicine. She developed one of the worldslargestPhase Iclinical trial programswhile at MDAnderson Cancer Center.Dr.Kurzrock also founded the UCSDs Center for Personalized CancerTherapy,focusing on genomicallydriven therapy as well as precisionimmunotherapy,especiallyinrare cancers. Dr. Kurzrock brought thefirst transcriptomicstudy totheclinic in an international settingspanning five countries(WINTHER),aswell as the first Nof1 study ofindividually customizedcombinationtherapy(IPREDICT). Dr.Kurzrockreceived her MD from theUniversity ofToronto,Canada. She has 900PubMed publications, an Hindexof 140, hasbeen namedto the lists ofmost highly cited scientists inthe world.Shehas auniquely strongrecord of competitivefunding with100 milliondollars inlifetimefunding, and has overseen earlydevelopment ofmultiple drugs thatarenow FDA approved.

Biography
Barrett Bready, was founder of Nabsys and CEO from 2005 until 2014 and then again starting in October, 2015. He grew Nabsys from a single employee to 50 and raised $50 million in venture financing to support the companys growth. Barrett Bready is an adjunct professor at Brown University where he teaches Biotechnology Management, a course on thebusiness of biotechnology. He serves as a commissioner of the I-195 Redevelopment District Commission, a large land redevelopment project in downtown Providence with a focus on life sciences and other high technology sectors. He has received numerous awards including, in 2011, Rhode Island Innovator of the Year from Providence Business News. Barrett Bready received an M.D. and an Sc.B. in physics from Brown University, both as part of Browns Program in Liberal Medical Education (PLME).

Biography
Mark Daly is an institute member and co-director of the Program in Medicaland Population Genetics at the Broad Institute of MIT and Harvard, where heleads many large-scale genome sequencing studies in autism and inflammatorybowel disease. He is also the founding chief of the Analytic andTranslational Genetics Unit (ATGU) at Massachusetts General Hospital andassociate professor at the Harvard Medical School. His research hashistorically focused on the development and application of statisticalmethods for the discovery and interpretation of genetic variationresponsible for complex human disease, and with the creation of the ATGU,he and other core faculty are focused on the interpretation of genomesequence and the use of genome information in clinical settings.Daly wasappointed director of the Institute of Molecular Medicine Finland (FIMM) atthe University of Helsinki from February of 2018 through April 2023 whilemaintaining his lab in Boston. After that, he returned to Boston full-timeand now maintains an affiliate position as a researcher at the Universityof Helsinki. FIMM is a translational research institute focusing on cancer,digital diagnostics, genetics, and epidemiology and is home to landmarkefforts such as the FinnGen Project.In addition to developing computationaland statistical methods that can be broadly applied, Dalys group hasseveral primary medical genetics research foci. He has an extensiveresearch program in neuropsychiatric geneticsparticularly in autism,schizophrenia, and ADHDand has led large-scale genome-wide associationstudies (GWAS) and exome sequencing efforts in this area. Dalys lab and BenNeale's lab together serve as an analytic hub for the Psychiatric GWASConsortium, an international consortium leading the largest collaborativeGWAS studies in five major psychiatric disorders. Daly also has alongstanding effort in the mapping of genes for Crohns disease andulcerative colitis, through which he helped found and lead an internationaleffort that has identified more than 150 genetic risk factors and, incollaboration with Ramnik Xaviers group, pursues the functionalinterpretation and clinical ramifications of these continued gene discoveryefforts. Along with Heidi Rehm, he is co-PI of the gnomAD project and iscommitted to ensuring the output of all ATGU genomic research is maximallyaccessible and useful to the clinical and research communities.Dalyreceived his B.S. in physics from MIT and his Ph.D. in human genetics fromLeiden University, Netherlands.

Biography
Professor Tabach leads the Deep Genomics Laboratory at the Hebrew University Medical School and is the founder of three companies specializing in genomics, cancer, and genetic diseases. He earned his PhD from the Weizmann Institute in systems biology and cancer, followed by postdoctoral training at Harvard Medical School in Professor Ruvkun’s lab, where he uncovered small-RNAi pathways and mechanisms underlying genetic diseases by developing multi-omics methodologies. His research identifies novel drug targets that reveal cancer vulnerabilities by deciphering the exceptional responder phenomenon- rare stage-IV patients who experience remarkable tumor regression - enabling the selective elimination of cancer cells while minimizing harm to healthy tissue. Through both academic work and entrepreneurial initiatives, Professor Tabach develops innovative solutions for cancer, aging, and genetic diseases by translating animal “super-traits” into RNA-based therapies for humans. His functional genomics discoveries have revealed key disease pathways and cancer genes, significantly advancing drug discoveries and personalized treatment.

Biography
Wei is an Assistant Professor in the Center for Genomic Medicine at Massachusetts General Hospital and Associate member in the Stanley Center for Psychiatric Research at Broad Institute of MIT and Harvard. She is co-leading the Global Biobank Meta-analysis Initiative (GBMI). As a statistical geneticist, Wei's research has mainly focused on developing and applying statistical methods to investigate the underlying genetic basis of complex human diseases and traits by leveraging large-scale biobanks and data sets.

Biography
Prof. Nilah Ioannidis has a joint appointment in EECS and the Center for Computational Biology (CCB). Her group works on computational methods to analyze and interpret personal genomes, including machine learning and deep learning methods to predict the clinical impact of genome variation and to model variation in gene expression and other molecular and cellular phenotypes.Dr. Ioannidis was previously a postdoctoral scholar in the Department of Biomedical Data Science at Stanford University, where she worked on several machine learning tools to predict the pathogenicity of single nucleotide variants, including the ensemble predictor REVEL for missense variants. During her PhD in Biophysics at Harvard University, she worked in the Department of Biological Engineering at MIT and developed methods to analyze the dynamics of intracellular particles using hidden Markov modeling and Bayesian inference. She also previously served as Research Director at the Jain Foundation, a non-profit foundation focused on the rare genetic disease dysferlinopathy.

Biography
Scott Gottlieb is a physician who served as the 23rd Commissioner of the U.S. Food and Drug Administration. He is currently a partner at New Enterprise Associates, and a senior fellow at the American Enterprise Institute. Dr. Gottlieb is a member of the board of directors for Pfizer, Inc., Illumina Inc., UnitedHealh Group, and NEA portfolio companies Tempus Labs, Aetion, Comanche Biopharma, Xaira and National Resilience. In addition, he serves on the boards of directors of Wesleyan University and the Mount Sinai Health System.Previously, he served as the FDAs Deputy Commissioner, a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services. He is the author of the New York Times bestselling book Uncontrolled Spread: Why COVID-19 Crushed Us, and How We Can Defeat the Next Pandemic, and a regular contributor to CNBC and CBS News Face the Nation.

Talk
Fireside Chat
Fireside Chat

Biography
Prof. Nilah Ioannidis has a joint appointment in EECS and the Center for Computational Biology (CCB). Her group works on computational methods to analyze and interpret personal genomes, including machine learning and deep learning methods to predict the clinical impact of genome variation and to model variation in gene expression and other molecular and cellular phenotypes.Dr. Ioannidis was previously a postdoctoral scholar in the Department of Biomedical Data Science at Stanford University, where she worked on several machine learning tools to predict the pathogenicity of single nucleotide variants, including the ensemble predictor REVEL for missense variants. During her PhD in Biophysics at Harvard University, she worked in the Department of Biological Engineering at MIT and developed methods to analyze the dynamics of intracellular particles using hidden Markov modeling and Bayesian inference. She also previously served as Research Director at the Jain Foundation, a non-profit foundation focused on the rare genetic disease dysferlinopathy.

Talk

Emerging Therapeutics Showcase:
Neosplice Therapeutics

Biography
Dr. Kim is physician-in-chief and senior vice president at City of HopeOrange County and vice physician-in-chief and professor at City of HopeNational Medical Center. Dr. Kim is an international leader in lungcancer having published over 200 peer-reviewed articles in top tierjournals. He has previously served as an associate tenured professor atThe University of Texas MD Anderson Cancer Center, Chair of Solid TumorOncology atLevineCancer Institute, Atrium Health, and obtained his MBAat theUniversity ofNorth Carolina Kenan-Flagler School of Business,ChapelHill, NC.

Talk

Emerging Therapeutics Showcase:
Neosplice Therapeutics

Biography
Ralph Snyderman served as Chancellor for Health Affairs at Duke Universityfrom 1989 to July 2004, leading the transition of this excellent medicalcenter into an internationally recognized leader in academic medicine. Heoversaw the development of the Duke University Health System and served asits first President and CEO. Dr. Snyderman has played a leading role in theconception and development of personalized healthcare, an evolving model ofnational healthcare delivery. He has been widely recognized for hiscontributions to the development of a more rational, effective, andcompassionate health care. He was among the first to envision andarticulate the need to shift the current focus of healthcare from treatingdisease events to personalized, proactive, and patient-centered care. TheAssociation of American Medical Colleges has referred to Dr. Snyderman asthe father of personalized medicine.

Talk

Emerging Therapeutics Showcase:
Neosplice Therapeutics

Biography
Scott Gottlieb is a physician who served as the 23rd Commissioner of the U.S. Food and Drug Administration. He is currently a partner at New Enterprise Associates, and a senior fellow at the American Enterprise Institute. Dr. Gottlieb is a member of the board of directors for Pfizer, Inc., Illumina Inc., UnitedHealh Group, and NEA portfolio companies Tempus Labs, Aetion, Comanche Biopharma, Xaira and National Resilience. In addition, he serves on the boards of directors of Wesleyan University and the Mount Sinai Health System.Previously, he served as the FDAs Deputy Commissioner, a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services. He is the author of the New York Times bestselling book Uncontrolled Spread: Why COVID-19 Crushed Us, and How We Can Defeat the Next Pandemic, and a regular contributor to CNBC and CBS News Face the Nation.

Talk

Emerging Therapeutics Showcase:
Neosplice Therapeutics

Biography
Dr. Kyle Farh is Vice President at Illuminas Artificial Intelligence (AI) Lab for Genome Interpretation, where he deciphers the clinical impact of genetic variants in rare and common diseases. Towards this goal, Kyle leads a multidisciplinary research team of deep learning scientists, statistical geneticists, and molecular biologists. Prior to joining Illumina, Kyle was an attending physician at Boston Childrens Hospital. Kyle completed his postdoc fellowship in Medical and Population Genetics at the Broad Institute, and received his PhD in Molecular Biology at MIT, MD at Harvard Medical School, and BS in Computer Science from Rice University.